Article
Takeda to Acquire Millennium for $8.8 Billion
Author(s):
Takeda Pharmaceutical Company Limited (Osaka, Japan) will acquire Millennium Pharmaceuticals, Inc. (Cambridge, MA), for approximately $8.8 billion through a cash tender offer of $25.00 per share.
Takeda Pharmaceutical Company Limited (Osaka, Japan) will acquire Millennium Pharmaceuticals, Inc. (Cambridge, MA), for approximately $8.8 billion through a cash tender offer of $25.00 per share. Through the deal, Takeda will acquire Velcade, primarily used as a second-line treatment for multiple myeloma and other drugs in Millennium’s pipeline for oncology and inflammatory disease.
After completion of the acquisition, Millennium will become a wholly owned subsidiary of Takeda and will continue operations in Cambridge, Massachusetts, as a standalone business unit. Millennium will be known as Millennium Pharmaceuticals, Inc., a Takeda Company.
The acquisition of Millennium is part of Takeda’s strategy to develop its oncology portfolio in the areas of oncology discovery, development, regulatory affairs, and commercialization.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
